ELI LILLY AND COMPANY Deferred Tax Liabilities, Net, Current
ELI LILLY AND COMPANY (LLY) had Deferred Tax Liabilities, Net, Current of $943.60 million as of 2015-09-30, per its 10-Q filed 2015-10-30.
Discontinued › Notes › Income Taxes
us-gaap:DeferredTaxLiabilitiesCurrent · last filed 2015-10-30
- 2015-09-30: Deferred Tax Liabilities, Net, Current $943.60M.
- 2015-06-30: Deferred Tax Liabilities, Net, Current $912.80M.
- 2015-03-31: Deferred Tax Liabilities, Net, Current $1.30B.
- 2014-12-31: Deferred Tax Liabilities, Net, Current $1.47B.
| Period end | Deferred Tax Liabilities, Net, Current |
|---|---|
| 2015-09-30 | $943.60M 10-Q · filed 2015-10-30 |
| 2015-06-30 | $912.80M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $1.30B 10-Q · filed 2015-04-30 |
| 2014-12-31 | $1.47B 10-Q · filed 2015-10-30 |
| 2014-09-30 | $1.35B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $1.04B 10-Q · filed 2014-07-28 |
| 2014-03-31 | $760.40M 10-Q · filed 2014-04-28 |
| 2013-12-31 | $792.80M 10-K · filed 2015-02-19 |
| 2013-09-30 | $841.90M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $913.60M 10-Q · filed 2013-07-26 |
| 2013-03-31 | $726.60M 10-Q · filed 2013-04-26 |
| 2012-12-31 | $1.05B 10-K · filed 2014-02-19 |
| 2011-12-31 | $422.30M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |